Posted by Michael Wonder on 11 Dec 2025
US FDA grants priority review to Bristol Myers Squibb's application for Opdivo (nivolumab) plus chemotherapy combination for classical Hodgkin's lymphoma
11 December 2025 - Bristol Myers Squibb today announced that the US FDA has accepted and granted priority review to the supplemental biologics license application for Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine for adult and paediatric (12 years and older) patients with previously untreated stage III or IV classical Hodgkin's lymphoma.
The FDA assigned a PDUFA goal date of 8 April 2026.
